Top

News & Events

Archive: 2013

News Archive

Imperial Innovations makes further investment in TopiVert

London, UK – Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), the leading technology commercialisation and investment group, has taken part in a further funding round in existing portfolio company TopiVert, which is developing topical anti-inflammatories for the treatment of diseases of the gastrointestinal tract and eye. In December 2011, Innovations invested £4m in TopiVert and in the current round has increased its total commitment to £8.5m cash. It is expected that this will be drawn down alongside further investment by existing investor SV Life Sciences, and new investors NeoMed Management and Johnson & Johnson Development Corporation (JJDC).  Following this, the carrying value of Innovations’ stake in TopiVert will be £8.6m.

Read more »

Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer

Sydney, Australia – Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).

Read more »

Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients

Lachen, Switzerland – Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis (RMS). Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.

Read more »

Imperial Innovations partners with Jetstream Capital for £5.1m funding round

London, UK – Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, is partnering with Jetstream Capital for a Series A investment round of £5.1 million ($8.4 million) into Econic Technologies Ltd.

Read more »

NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis

Aberdeen, UK –  NovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced it has initiated the development of an inhaled form of Lynovex, its treatment for cystic fibrosis (CF).

Read more »

Imperial Innovations Group plc Leads £17.5m Funding Round for Crescendo Biologics

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), the leading technology commercialisation and investment group, has led a £17.5m ($28m) Series A financing for new portfolio company Crescendo Biologics (‘Crescendo’), the Cambridge-based developer of human antibody fragment therapeutics. Innovations has committed £6.5m ($10m) in the round and was joined by new investor Astellas Venture Management as well as existing investor Sofinnova Partners. Following completion of the investment, Innovations will hold a 26.9% share in Crescendo.

Read more »

AmpliPhi Biosciences Announces $18 Million Private Placement

Richmond, VA, US, Colworth, UK and Sydney, Australia –  AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a private placement financing. Pursuant to the stock purchase agreement, the Company will issue an aggregate of 72,003,000 shares of the Company’s common stock at a price per share of $0.25. Estimated net proceeds from the placement will be $16.9 million.

Read more »

NOXXON Pharma: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in CLL and MM Studies

Berlin, Germany - NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology (ASH) in New Orleans, LA, USA from 7-10 December 2013.

Read more »

Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar

Paris, France – Nanobiotix (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today, in accordance with its plans, the selection of its new product, NBTX-TOPO, in view of its preclinical development.

Read more »

GE Healthcare Scientist Paired with Welsh MP to Share Insights on Science and Policy-Making

Cardiff, UK – Dr Nina Moran from GE Healthcare Life Sciences will be swapping a lab coat for legislation, when she visits Mr Roger Williams MP for Brecon and Radnorshire, at the House of Commons for a “Week in Westminster” as part of a unique ‘pairing’ scheme run by the Royal Society – the UK’s national academy of science.

Read more »

Roche and Molecular Partners enter into alliance to develop new cancer treatments

Basel, Switzerland, Zurich-Schlieren, Switzerland - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Molecular Partners AG today announced that they have entered  into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin® biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

Read more »

MRCF Invests AU$1m in Antibiotics Start-Up Auspherix

Sydney, Australia − Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease was launched today with AU$1 million in start-up financing from Australia’s Medical Research Commercialisation Fund (MRCF).

Read more »

College Hill Life Sciences Adds Five New Clients to Its Roster

London, Manchester, Munich, Boston, Sydney, Melbourne: The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, continues to expand its portfolio with five additional client wins during the last three months. New client mandates span the Consultancy’s offering from fully retained services to branding and ad hoc projects.

Read more »

JHL Biotech Selects GE’s FlexFactory™ Biomanufacturing Platform for Taiwan Facility

Chalfont St Giles, UK and Hsinchu, Taiwan – GE Healthcare Life Sciences, (NYSE: GE), and JHL Biotech today announced that GE Healthcare has completed installation of its FlexFactory™ biomanufacturing platform at JHL Biotech’s Research Center and manufacturing plant in Hsinchu, Taiwan.  The new manufacturing platform will follow current good manufacturing practices (cGMP) and be fully operational by the end of 2013.  It is similar to the production process at JHL Biotech’s KUBio modular biopharmaceutical factory currently under construction by GE Healthcare at the Biolake Science Park in Wuhan, China.

Read more »

Telormedix Raises CHF 6 M ($ 6.6 M) in Series B Financing Round

Bioggio, Switzerland – Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised CHF 6 Million in an extension to its Series B financing from existing investors Aravis Venture (Zurich, Switzerland) and Proquest Investments (Princeton, USA). The funds will be used to support the on-going Phase II clinical trial of TMX-101 for the treatment of carcinoma in situ (CIS) in the bladder and to finance the planning of a follow on trial for patients with CIS, expected to start in 2014.

Read more »

Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology

Sydney, Australia – Novogen Limited (ASX: symbol NRT; Nasdaq: symbol NVGN) today announced the filing of a family of provisional patents in the US covering anti-tropomyosin (ATM) drug technology.

Read more »

Novogen Announces That CanTx Drug Destroys Ovarian Cancer Stem Cell Spheroids

Sydney, Australia – Novogen Limited (ASX: symbol NRT; Nasdaq: symbol NVGN) today reported that its US subsidiary, CanTx, has found that lead drug candidate Trilexium is highly effective at destroying ovarian cancer spheroid architecture.

Read more »

Prosensa and Partners Awarded Second European Consortium FP7 Research Grant

Leiden, The Netherlands and Newcastle, UK – Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, and Newcastle University, UK, have announced the award of a second Framework Programme 7 (FP7) research grant from the European Commission. This new FP7 research grant totals approximately EUR 6 million to support the development of imaging biomarkers for Duchenne muscular dystrophy (DMD).

Read more »

Oxford Immunotec trading commences on NASDAQ

London, UK – Imperial Innovations Group plc (AIM: IVO, “Innovations”, “the Group”), the leading technology commercialisation and investment group, notes that its portfolio company Oxford Immunotec (“OI”) has successfully listed its shares on the NASDAQ Stock Market.  Trading in the shares started earlier today under the symbol "OXFD". Innovations has not sold any of its OI shares during the listing process and now owns a stake of 5.1%.

Read more »

Award wins for College Hill Clients: November

London, Manchester, Munich and Melbourne: November was a good month for award wins for College Hill Life Sciences’s clients, with Prosensa winning the Best SME Biotech Pipeline at the 2nd Annual Rare & Orphan Advocacy and Research (ROAR) Awards and Mesoblast winning Financial Deal of the Year at the 9th Annual SCRIP Awards.

Read more »

Dr Nigel Ramsden joins SYNthesis med chem as Head of European Operations

Cambridge, UK, Shanghai, China & Melbourne, Australia – SYNthesis med chem, the global contract research organisation providing synthetic and medicinal chemistry services, today announced that the company has appointed Dr Nigel Ramsden as Vice President of Medicinal Chemistry and Head of European Operations.

Read more »

Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis

Abingdon, UK –  Atopix Therapeutics Ltd (“Atopix”), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, today announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).
 

Read more »

Source BioScience plc: Interim Management Statement

Nottingham, UK − Source BioScience plc (LSE: SBS), the international laboratory services and products business, today publishes its Interim Management Statement for the year to date.
 

Read more »

Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the quarter ending September 30, 2013.

Read more »

MISSION Therapeutics Secures £20 Million ($32 Million) in Series B Financing to Drive Development of Ubiquitin Pathway Inhibitors

Cambridge, UK – MISSION Therapeutics Limited (MISSION), a biotechnology company developing novel inhibitors of deubiquitylating enzymes (DUBs) involved in the DNA damage response, announced that it has closed a Series B round of equity financing totalling £20 million ($32 million).   New investor Pfizer Venture Investments joined existing investors Sofinnova Partners, Imperial Innovations (AIM: IVO, ‘Innovations’), S.R. One and Roche Venture Fund, which all participated in the financing.

Read more »

Imperial Innovations Group plc: MISSION Therapeutics receives £20m Series B funding

London, UK – Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, has increased its support for MISSION Therapeutics by committing £4.5m of a £20m funding round. Innovations had previously participated in a £6m round for MISSION in August 2011. MISSION is a biotechnology company developing drugs that target a cell’s response to DNA damage. Innovations is joined in the round by new investor Pfizer Venture Investments and other existing investors Sofinnova Partners, SR One and Roche Venture Fund.

Read more »

Prosensa Awarded Best SME Biotech Pipeline 2013 at the Rare & Orphan Advocacy and Research (ROAR) Awards

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, has been awarded Best SME Biotech Pipeline 2013 in the Rare & Orphan Advocacy and Research (ROAR) Awards.

Read more »

Novogen Announces Important Discovery in Program to Develop Drugs Against Genetic and Degenerative Disorders

Hornsby, Australia – Novogen Limited (ASX:NRT, NASDAQ: NVGN) is engaged in a pilot program aimed at the breakthrough development of drugs to treat a wide range of genetic and non-genetic degenerative diseases including muscular dystrophy, motor neurone disease, Huntington’s Disease, cystic fibrosis and Alzheimer’s Disease. The program has returned positive findings, with a pilot drug proving to be highly cytotoxic against the initial screen: stem cells from a neuromuscular dystrophy disease.

Read more »

Toumaz: UK Patient Safety to be Boosted by Wireless Vital Signs Monitor

Abingdon, UK – A new vital signs monitor has gained regulatory approval. This wireless device, about the size of a sticking plaster, helps rapidly detect deterioration of patients in hospital, and aims to improve patient safety and reduce the length of stay. The first UK pilot of this device has just been announced with Spire Healthcare.

Read more »

2013 FDA Approval Rates Suggest Record Year for Post-Launch Success

London, Boston, Tokyo — A focus on hard to treat or specialist diseases is set to result in record post-launch sales for new drugs in 2013, according to newly-released report, “FDA Approval Rates: Niche Products Driving Record Success,” from EP Vantage, the editorial arm of Evaluate. While the total tally of approved drugs and biologics for 2013 is not forecast to match last year’s record of 43, the combined US sales for this year’s approved products could surpass $18bn five years after launch.  The report, based on market intelligence and analysis from EvaluatePharma , can be downloaded at http://www.evaluategroup.com/EPVantage-FDA-Approvals.

Read more »

GE Healthcare Life Sciences Launches Xuri™ Technology Family for Cell Therapy Manufacturing

Chalfont St Giles, UK – GE Healthcare Life Sciences today launched Xuri™, a new technology family designed specifically to support and advance the field of cell therapy.  The new technology family, in which the first product is the Xuri Cell Expansion System W25 for the manufacture of cellular immunotherapies in a clinical setting, will combine GE Healthcare’s capabilities in cellular science with the company’s expertise in the development of advanced tools for the manufacture of biopharmaceuticals.

Read more »

Scil Proteins Production to Join WACKER Creating Leading Microbial-based Biopharmaceutical Manufacturer

Halle, Germany – Scil Proteins Production, a private contract manufacturer of recombinant proteins, today announced that Wacker Biotech GmbH, a subsidiary of Wacker Chemie AG, has acquired 100% of its shares from the sole holder in the Company, BioNet Ventures GmbH. The transaction is expected to close at the beginning of 2014. Both companies are committed to a seamless transfer of business assets, as well as a smooth transition for the employees to WACKER.

Read more »

Karus Therapeutics Appoints Penelope Ward as CMO

Oxford, UK – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced that Penelope Ward has joined the Company in the role of Chief Medical Officer. Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory Board, appointment of additional R&D personnel and a move to a world-class biotech hub near Oxford.

Read more »

NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

Paris, France – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.

Read more »

College Hill Life Sciences Targets Asian Markets and Attends BIOChina

London, Manchester, Munich, Melbourne: College Hill Life Sciences, part of the international business communications consultancy, College Group, is pleased to announce its participation in the UK Trade and Investment (UKTI) Mission to China 11-15 November as it increases its focus on Asia, following College Group’s expansion in the region with the acquisition of PR People.

Read more »

Prosensa Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the successful enrollment of the 100th  patient into the Natural History Study of Duchenne muscular dystrophy (DMD).

Read more »

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology

Lausanne, Switzerland and South San Francisco, CA, USA –  ADC Therapeutics Sarl (‘ADC Therapeutics’), a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), and Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

Read more »

Polyphor and Roche Join Efforts to Combat Multidrug-Resistant Bacterial Infections

Allschwil, Switzerland – Polyphor Ltd, a privately held pharmaceutical company, and Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor’s investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa.

Read more »

College Hill Life Sciences celebrates Gold win with GE Healthcare Life Sciences

London, Manchester, Munich, Melbourne: Having supported GE Healthcare Life Sciences to promote its cell technologies products for the last five years, College Hill Life Sciences, part of the international business communications consultancy, College Group, was pleased to join its client in celebrating winning gold for the Best Healthcare Campaign at this year’s CIPR PRide Awards for Thames and Chiltern.

Read more »

Hookipa Biotech Closes €20 Million ($27.5 Million) in Series B Financing

Vienna, Austria – Hookipa Biotech AG, a company pioneering a new class of vaccines, today announced that it has raised €20 million ($27.5 million) in a series B equity financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing with three new investors, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.

Read more »

Scil Proteins and LEUKOCARE: Novel Recombinant Human Thrombin Provided in Innovative Stabilized Formulation

Halle, Germany, and Munich, Germany – Scil Proteins GmbH and LEUKOCARE AG, two German based life science companies, today announced results of their strategic partnership to develop a stabilized recombinant human thrombin (rhThrombin). The new, proprietary and highly cost-effective bacterial manufacturing process of rhThrombin is a recent in-house development of Scil Proteins. This recombinant production process does not rely on bovine or human blood derivatives and can be scaled up easily to meet market demands. Combining rhThrombin with a formulation of LEUKOCARE’s proprietary Stabilizing and Protecting Solutions (SPS) technology results in increased stability during storage at elevated temperatures as well as during terminal sterilization by irradiation. This offers various opportunities for novel formulations and advanced functionalized medical devices.

Read more »

Protego Launched with Start-up Investment from the MRCF to Develop Sternal Device for Cardiac Surgery

Melbourne, Australia – Protego Medical Pty Ltd, an early stage medical technology company developing a medical device for sternal protection during cardiac surgery, was launched today with AU$2M start-up financing from Australia’s Medical Research Commercialisation Fund (MRCF). At the same time, the Company announced the appointment of Pablo Solis as CEO.

Read more »

e-Therapeutics starts phase IIb trial of ETS6103 in major depressive disorder

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX) announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder. The trial is evaluating ETS6103 as a second-line treatment for patients who have not responded adequately to first-line therapy with an SSRI (selective serotonin reuptake inhibitor). It is being conducted by a group of primary care centres with a history of involvement in depression studies in the Glasgow area of Scotland.

Read more »

NovaBiotics’ Lynovex® Gains Support From The UK’s Cystic Fibrosis Trust

Aberdeen and London, UK  – NovaBiotics Ltd, the clinical-stage biotechnology company, today announced that it has partnered with the Cystic Fibrosis Trust and Health Sciences Scotland, for a Phase1/2a clinical trial of its novel compound, Lynovex®.

Read more »

Accentus Medical: Agluna® Treated Devices Significantly Reduce Infection Rates

Oxford, UK – Accentus Medical is pleased to announce the results of a retrospective review of infection rates associated with orthopaedic limb salvage devices treated with its innovative Agluna® surface technology.  Agluna® harnesses the anti-microbial properties of silver ions in preventing device related infection. The technology is supplied by Accentus Medical under licence to Stanmore Implants Worldwide on its custom patient specific limb salvage devices.

Read more »

OGT strengthens focus on cancer biomarkers

Oxford, UK – Oxford Gene Technology (OGT), a provider of innovative genetics research and biomarker solutions to advance molecular medicine, today announced the appointment of Dr Bob Holland as Chief Medical Officer.

Read more »

AmpliPhi Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies Targeting C. Difficile

Richmond, VA, US, Colworth, UK and Sydney, Australia  – AmpliPhi BioSciences Corporation (OTC: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat antibiotic resistant infections, announces it has entered into Collaboration and License Agreements with UK-based University of Leicester to develop a novel bacteriophage therapy targeting Clostridium difficile (C. difficile), a serious gastrointestinal infection for which new treatments are urgently required.

Read more »

Imperial Innovations Group plc: Nigel Pitchford and Tony Hickson Appointed Directors

London, UK - Imperial Innovations Group plc (“Innovations”, AIM: IVO), one of the leading technology transfer and commercialisation companies in the UK, has appointed Dr Nigel Pitchford and Tony Hickson directors with immediate effect.

Read more »

Imperial Innovations Group plc: Oxford Immunotec makes public S-1 filing for potential IPO on NASDAQ

London, UK - Imperial Innovations Group plc (AIM: IVO, "Innovations") is pleased to note that on 15 October, portfolio company Oxford Immunotec filed publicly its S-1 with the U.S. Securities and Exchange Commission (SEC), and is considering an Initial Public Offering (IPO) on the NASDAQ Stock Market.

Read more »

Imperial Innovations Group plc: Full Year Results

London, UK - Imperial Innovations Group plc (AIM: IVO, “Innovations” or “the Group”), a leading technology commercialisation and investment group, has published its results for the year ended 31 July 2013.

Read more »

e-Therapeutics’ interim results for the six months ended 31 July 2013

Oxford and Newcastle, UK - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its interim results for the six months ended 31 July 2013.

Read more »

Auven Therapeutics Announces AstraZeneca’s MedImmune Acquires Antibody-Drug Conjugate Company Spirogen and Invests in ADC Therapeutics

Lausanne, Switzerland, London, UK, St Thomas, U.S. Virgin Islands, and New York, USA − Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs addressing unmet medical needs, today announced that its strategic investment in the antibody-drug conjugate (ADC) field has been validated by the sale of its platform technology portfolio Company Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca.

Read more »

BioInvent and Bayer Extend and Broaden Collaboration for the Discovery and Development of Therapeutic Antibodies

Lund, Sweden – BioInvent International AB (OMXS: BINV) today announces that it has signed an extension to its 2008 license agreement with Bayer Pharma AG for the development of antibodies from BioInvent's n-CoDeR® libraries. Under the terms of the extension, Bayer will broaden its access to BioInvent's discovery and development technology platform.

Read more »

College Hill Improving Ranking in Mergermarket M&A deals league tables

London: College Hill, part of the International business communications consultancy College Group, is pleased to have seen its ranking maintained or improved in this year’s Mergermarket league tables of the top M&A deals. The ranking were based on work undertaken by College Hill’s team between the 1st of January and the 30th of September 2013.

Read more »

OBN Annual Awards Dinner 2013: College Hill Congratulates Three of Its Clients on Their Wins

London & Manchester, UK: College Hill Life Sciences is pleased to congratulate three of its clients on their wins at the UK’s OBN Annual Awards Dinner 2013.  The awards seek to highlight the many achievements and major success stories of the UK’s bioscience sector in raising funds, executing deals and supporting innovation.

Read more »

TranScrip Partners Announce Hong Kong Expansion

Hong Kong –  TranScrip Partners, Reading UK, the specialist contract organisation today announced the opening of its Hong Kong office, TranScrip Partners Hong Kong Ltd. The new branch of TranScrip Partners will be led by James Thorburn, who has over 25 years’ experience in clinical research and development involving drugs and medical devices, as well as a successful record of establishing contract research organisations both in the UK and his native Hong Kong. As part of his extensive experience in Hong Kong, James helped to establish the Clinical Trials Centre of the Faculty of Medicine, The University of Hong Kong, and currently serves as Hong Kong’s Regional Director for PACRA (Pan Asian Clinical Research Association). In his new role, James will be supporting TranScrip’s continuing interests in the APAC region, including China and India and will be working closely with TranScrip Partners Australia who are all already running projects in the APAC region.

Read more »

Karus Therapeutics wins ‘Best Biotech Fundraiser’ award

Oxford, UK – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has won ‘Best Biotech Fundraiser’ at this year’s OBN Awards ahead of shortlisted candidates e-Therapeutics and Heptares Therapeutics.

Read more »

Imperial Innovations Group plc: Circassia’s Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season

London, UK − Imperial Innovations Group plc (AIM: IVO, “Innovations”), the leading technology commercialisation and investment group, announces that portfolio company Circassia, the specialty biopharmaceutical company focused on allergy, has achieved successful results from a large phase II clinical study of its grass allergy treatment.

Read more »

Xenios and LEUKOCARE Announce Strategic Partnership in the Field of Anti-Inflammatory Coatings for Next Generation Extracorporeal Support Systems

Heilbronn, Germany, Munich, Germany− Xenios AG and LEUKOCARE AG, two German based life science companies, announced today a strategic alliance for the development and marketing of Xenios’ extracorporeal support systems with LEUKOCARE’s anti-inflammatory surface coating. LEUKOCARE has granted to Xenios a worldwide license of its relevant patents and know-how with exclusivity for anti-inflammatory surfaces. Moreover, Xenios has assigned LEUKOCARE with the adaptation of the clinically proven coating technology to Xenios’ broad range of medical devices that will be commercialized under Novalung, Medos and further Xenios brands.

Read more »

GE Healthcare Life Sciences to build KUBio modular biopharmaceutical factory for JHL Biotech in China

Chalfont St Giles, UK and Wuhan, China – GE Healthcare Life Sciences, a business unit of GE Healthcare (NYSE: GE), and JHL Biotech, a provider of biopharmaceutical process development and manufacturing services, today announced that a KUBio™ modular biopharmaceutical factory will be built in China for JHL Biotech. The site for the new factory, which will be fully operational beginning early 2015, is the Biolake Science Park in Wuhan, China.

Read more »

Clinigen Group plc: Preliminary Results for the year ended 30 June 2013

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN), the global specialty pharmaceuticals business, has today published its preliminary results for the 12 months ended 30 June 2013.

Read more »

Imperial Innovations Group plc: Portfolio Company IXICO Expands into Digital Healthcare

London, UK – Imperial Innovations Group plc (AIM: IVO, "Innovations") portfolio company IXICO Limited, a medical imaging analysis company, is to be acquired by Phytopharm plc (AIM: PYM) in a proposed reverse takeover announced today. The enlarged Phytopharm group, to be renamed IXICO plc, will benefit from a strengthened balance sheet to grow its clinical trial services business and to bring new technology solutions to the diagnosis of dementia and other conditions. The newly-quoted IXICO plc will use the new ticker 'IXI'.

Read more »

Accentus Medical Announces Completion of Management Buyout

Oxford, UK – Accentus Medical, a global leader in silver-based anti-microbial implant surfaces, has announced today the successful completion of a management buyout. The buyout was delivered through a combination of investment from the incumbent management team, and a spectrum of private investors with knowledge and expertise in the implantable medical device market and advanced materials sector. The buyout transaction eliminates historic debt and provides the company with fresh equity investment to take forward the business plan.

Read more »

Nanobiotix Strengthens Its Management Team

Paris, France – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the strengthening of its management team to support the company’s growth within its business strategy.

Read more »

Evaluate: Fall in Licensing Deals Characterizes First Half of 2013 in the Pharmaceutical Sector

London, Boston, Tokyo — Despite a positive start to the year characterized by healthy IPO activity and free-flowing venture capital, licensing deals, the life blood of the industry, have stalled, signaling that rising valuations could be pricing buyers out of the market. The industry now faces the second half with cautious optimism over its ability to sustain some of the buoyancy seen in the first half , according to the newly released, “Pharma Half-Year Review 2013” report from Evaluate’s editorial arm, EP Vantage. The report, based on data from EvaluatePharma, is available for download at http://www.evaluategroup.com/PharmaHalfYearReview.

Read more »

Source BioScience plc: Recommended Cash Offer for Vindon Healthcare plc - Offer Declared Unconditional in All Respects

Nottingham, UK − Source BioScience plc (LSE: SBS) the international diagnostics and genetic analysis services business, announces that its circa GBP 12.2 million recommended cash offer for Vindon Healthcare plc is now declared unconditional in all respects.

Read more »

Clinigen Group on Track with European Marketing Authorization Transfers for Cardioxane and VIBATIV

Burton-on-Trent, UK – Following the acquisition of Cardioxane® from Novartis and the in-licensing of VIBATIV® from Theravance, Inc. in March 2013, Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) today reported significant progress in the handover of these products with the transfer of key Marketing Authorizations in Europe to Clinigen. The transfers have progressed according to internally agreed timelines and both projects are continuing on schedule.

Read more »

Source BioScience: Recommended Cash Offer For Vindon Healthcare plc - Offer Declared Unconditonal As To Acceptances

Nottingham, UK − On 7 August 2013 the Boards of Source BioScience and Vindon announced the terms of a recommended cash offer to be made by Source BioScience for the entire issued ordinary share capital of Vindon at 13.7p per Vindon Share. The full terms of, and conditions to, the Offer together with the procedure for acceptance were set out in the Offer Document issued by Source BioScience on 7 August 2013 and in respect of Vindon Shares held in certificated form, in the Form of Acceptance.

 

Read more »

College Hill Life Sciences Adds To Its Portfolio with 10 New Clients

London, Manchester, Munich, Boston, Sydney, Melbourne: The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, continues to expand its portfolio with 10 additional client wins during the last three months. New client mandates span the Consultancy’s offering from fully retained services to branding and ad hoc projects.

Read more »

LGC and TranScrip Partners agree strategic alliance to enhance anti-infective and respiratory offerings

Reading, UK –  LGC, an international leader in the laboratory services, measurement standards, reference materials, genomics and proficiency testing marketplaces, and TranScrip Partners, a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management, have today announced a strategic alliance which will allow both parties to combine and enhance their offerings to clients, particularly in the areas of anti-infectives and respiratory disease.

Read more »

MedTech Sector Stalled by Significant Drop in FDA Approvals, M&A Slowdown

London, UK and Boston, US — Despite most large-cap medtech companies seeing reliable share price growth, 2013 has been a disappointing year so far for the medical technology industry, according to the newly released “MedTech Half Year Review 2013” report from Evaluate’s editorial arm, EP Vantage. Not only did the sector experience a steep decline in FDA-approved medical technologies,  the low number of completed mergers and acquisitions puts 2013 on track to be the most disappointing year for M&A activity in a decade.  The report, based on data from EvaluateMedtech, can be viewed at http://www.evaluategroup.com/MedTechHalfYearReview.

Read more »

Seven College Hill Life Sciences' Clients Shortlisted for 2013 SCRIP Industry Awards

London, Manchester, Munich, Boston, Sydney, Melbourne: College Hill Life Sciences’ clients are again well represented this year in the list of finalists for the Scrip Awards, with Clinigen, e-Therapeutics, Mesoblast, Molecular Partners, Prosensa, Roche, and Vaxxas racking up 10 places on short lists between them, following the entries spearheaded  by College Hill.

Read more »

Imperial Innovations leads £8m series ‘C’ funding round in Plaxica

London, UK – Imperial Innovations Group plc (AIM: IVO, ‘Innovations’), a leading technology commercialisation and investment group, has led an £8m funding round in Plaxica, a technology and licensing company focused on the production of next generation biopolymers and platform chemicals from renewable resources. Innovations has committed close to £3.9m, alongside existing investors Invesco Perpetual and NESTA Investments who contributed £3.9m and £0.25m respectively.

Read more »

SYNthesis Med Chem Opens New Facility in Cambridge, UK

Cambridge, UK, Shanghai, China & Melbourne, Australia – SYNthesis med chem, the global contract research organisation providing synthetic and medicinal chemistry services, today announced that the company has opened a new facility at the Babraham Research Campus in Cambridge, UK.

Read more »

Clinigen Group Selected to Manage Access Program by Eisai for Fycompa (perampanel) in Germany

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) today announced that it has signed an agreement with Eisai EMEA to exclusively manage an access program for Eisai’s anti-epilepsy drug Fycompa (perampanel) in Germany, ensuring an uninterrupted supply of the drug at no cost to the German healthcare system, following the temporary suspension of commercial distribution in the country.

Read more »

Prosensa Initiates First Patient Dosing in Phase I/II trial of PRO053

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the dosing of the first patient in its Phase I/II clinical trial of PRO053, an exon-skipping compound for the treatment of Duchenne muscular dystrophy (DMD).

Read more »

Nexus6 Steps Up its Global Presence with Three New Appointments

Auckland, New Zealand – Nexus6 Ltd, a digital health company dedicated to improving respiratory care, today announced three appointments to its senior management team, following the Company’s successful US$3.6m financing earlier in 2013.

Read more »

Clinigen Group plc - Notification of Full Year Results Date

Burton-on-Trent, UK – Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and services company, will announce its full year results for the period ended 30 June 2013 on Wednesday, 25 September 2013.

Read more »

Clinigen Group plc - Appointment of Peel Hunt as Joint Broker

Burton-on-Trent, UK – Clinigen Group plc ( “Company”, AIM: CLIN), the global specialty pharmaceuticals and services company, is pleased to announce that it has appointed Peel Hunt LLP as joint broker, alongside Numis Securities Limited, with immediate effect. Numis continues to act as Nominated Adviser to the Company.

Read more »

Mind-NRG Successfully Completes 6 Million Euro Series B Financing

Geneva, Switzerland – Mind-NRG, the Swiss-based company focusing on developing neuregulins to treat neurodegenerative diseases, announces the close of its Series B financing raising 6 Million EUR (~8 Million USD). The financing was led by new investor LRM, a Belgian based investor specialising in Life Sciences, along with existing investor and leading venture capital firm Index Ventures.

Read more »

LEUKOCARE announces EUR 3.4 M capital increase

Munich, Germany − LEUKOCARE, a leading provider of stabilizing and protecting formulation technologies for biologics, announced the successful completion of its capital increase of EUR 3.4 million. New ordinary shares were issued to existing shareholders and new investors in exchange for a combination of new equity capital and the conversion of an outstanding EUR 1.0 million corporate bond.

Read more »

Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis

Bristol, UK and Hasselt, Belgium – Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467. Examination of the MRI results (new Gd and total Gd enhancing lesions) demonstrated a significant decrease in the number of contrast-enhancing brain lesions (CEL) in patients with relapsing multiple sclerosis treated by intradermal injection of ATX-MS-1467. The same effect was not seen in the subcutaneously dosed group. These encouraging results will now need confirmation in appropriate Phase II trials.

Read more »

TranScrip Partners Announce Australian/Asian Appointment

Sydney, Australia – TranScrip Partners, Reading UK, the rapidly growing, cutting-edge contract organisation today announced the appointment of a new Senior Partner in Australia, Dr Glen Pater, a pharmaceutical physician with 25 years industry experience and a successful track record in drug development and life cycle management having been responsible for supporting several major Pacific Asia launches for big pharma. The appointment of a Senior Partner to the Australian office of TranScrip will therefore offer a substantial gateway to Asia. “This will allow us to better support our clients and their global programmes and add to the depth and breadth of our expertise in drug development and commercialisation”, said TranScrip’s Managing Partner, Dr Flic Gabbay.

Read more »

Nanobiotix Half Year Results for the period ended 30 June 2013

Paris, France – NANOBIOTIX (the “Company”) (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has published today its half year results for the six month period ended 30 June 2013 (HY1).

Read more »

New number of shares and votes in BioInvent International AB (publ)

Lund, Sweden – BioInvent International AB (publ) (OMXS:BINV) today announced that the company’s total number of shares as per 30 August 2013 amounts to 85,014,649 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the rights issue of 10,560,826 shares with preferential right for the company’s shareholders that was announced on 19 June 2013 and the additional 528,041 shares that were issued in a so-called over-allotment option in connection to the rights issue.

Read more »

Source Bioscience plc Recommended Cash Offer for Vindon Healthcare plc - First Closing Date Announcement

Nottingham, UK − Background: On 7 August 2013 the Boards of Directors of Source BioScience and Vindon announced the terms of a recommended cash offer to be made by Source BioScience for the entire issued ordinary share capital of Vindon at 13.7p per Vindon Share (the "Offer"). The full terms of, and conditions to, the Offer together with the procedure for acceptance were set out in the offer document issued by Source BioScience on 7 August 2013 (the "Offer Document")  and in respect of Vindon Shares held in certificated form, in the form of acceptance.

Read more »

Dezima Pharma Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001

Naarden, The Netherlands – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease (CVD) in patients with mild dyslipidemia.

Read more »

Source BioScience plc: Half Year Report for the Six Months Ended 30 June 2013

Nottingham, UK − Source BioScience plc (LSE: SBS) the international diagnostics and genetic analysis services business, announces its Half Year Report for the six months ended 30 June 2013.

Read more »

NovaBiotics Enters into Agreement with Taro

Aberdeen, UK – NovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that it has entered into an exclusive agreement with Taro Pharmaceuticals North America, Inc. (“Taro”) to licence and co-develop Novexatin®, the Company’s first-in-class antifungal peptide treatment for fungal nail infections.  Novexatin® is an investigational drug that is expected to enter a multi-centre Phase IIb study for mild-to-moderate onychomycosis in the US. NovaBiotics and Taro will jointly manage the study and other development activities for Novexatin®, with Taro as lead partner in the programme.

Read more »

Prosensa Announces Second Quarter 2013 Financial Results and Recent Corporate Developments

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the quarter ended June 30, 2013.

Read more »

Source BioScience plc - Result of Open Offer

Nottingham, UK – In relation to the Open Offer announced on 7 August 2013, of up to 10,778,066 New Ordinary Shares, the Company announces that it has received valid applications in respect of 8,090,699 Open Offer Shares from Qualifying Shareholders, raising gross proceeds of approximately £0.77 million.  This represents approximately 75 per cent. of the Open Offer Shares offered. All eligible applications received from Qualifying Shareholders will therefore be allocated their pro rata Open Offer Entitlements and all eligible applications under the Excess Application Facility will be allocated their Open Offer Shares as applied for.

Read more »

Source BioScience plc - Result of General Meeting

Nottingham, UK – The Board of Source BioScience  announces that at the General Meeting of the Company held earlier today all resolutions were passed as follows:

Read more »

Karus Therapeutics Secures Prominent Role in Epigenetics Debate at SciBX Summit 2013

Oxford, UK – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced its engagement with the “Epigenetics’ Second Wind” debate at the SciBX Summit on Innovation in Drug Discovery and Development to be held in Boston, USA, on 29-30 October.

Read more »

Prosensa Holding N.V. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on August 28, 2013

Leiden, The Netherlands − Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Wednesday, August 28, at 8:00am EDT to report its second quarter financial results and provide a corporate update.

Read more »

GE Healthcare Life Sciences, Osaka University Team Up to Develop Future Leaders of Japan’s Life Sciences Sector

Uppsala, Sweden – 19 August 2013 – GE Healthcare Life Sciences today announced a joint program with Osaka University to offer students access to GE Healthcare’s cutting-edge expertise in training and technologies for biopharmaceutical research and manufacturing, to help support future growth of the sector in Japan.  The program, Interdisciplinary Program for Biomedical Sciences (IPBS), is Osaka University’s government-funded commitment to graduate education, which aligns with GE Healthcare Japan’s “Life Sciences Academy,” a GE Healthcare initiative launched in April 2012 with the objective of supporting the development of life sciences researchers in Japan.  Of the 14 IPBS graduate students, four will visit GE Healthcare Life Science’s Uppsala site for three weeks from 19 August to 6 September 2013.

Read more »

College Hill Ranked 10th Largest UK Healthcare Consultancy by PR Week

London: College Hill, part of the International business communications consultancy College Group, is pleased to have been moved up several places to 10th position in this year’s PR Week’s league table of the top 25 UK healthcare consultancies, based on 2012 gross revenues for healthcare PR work undertaken by College Hill’s Life Sciences team. Income generated by the life sciences team represents a 14% increase in College Hill’s healthcare revenues over 2011.

Read more »

caprotec bioanalytics and Syngenta announce research collaboration

Berlin, Germany – caprotec bioanalytics GmbH and Syngenta International AG announced today a joint research agreement in which Syngenta will gain access to caprotec’s proprietary Capture Compound Mass Spectrometry (CCMS) technology. The companies will work together to profile the interactions of one of Syngenta’s novel active compounds with the proteome in its relevant plant biological system. caprotec’s platform allows an unbiased evaluation of the interactions of small molecules with protein mixtures in a targeted and directed manner, thereby facilitating the identification and elucidation of tractable targets as well as accelerating the development of promising leads.

Read more »

AmpliPhi Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis

Richmond, VA, US, Sydney, Australia, London, UK – AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment of Pseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held in Olympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients.

Read more »

Source BioScience plc: Recommended Cash Offer for Vindon Healthcare

Nottingham, UK – The Boards of Source BioScience and Vindon are pleased to announce that they have reached agreement on the terms of a recommended offer, to be made for the entire issued and to be issued share capital of Vindon not already owned by Source BioScience for cash consideration of approximately £12.2 million (the “Offer”).

Read more »

Source BioScience plc: Announcement of Open Offer to Raise up to Approximately £1 million Before Expenses through the Issue of up to 10,778,066 New Ordinary Shares

Nottingham, UK – The Board announces an open offer (the “Open Offer") of up to 10,778,066 ordinary shares of 2 pence each (the “New Ordinary Shares”) at an issue price of 9.5 pence (the “Issue Price”) per New Ordinary Share to all eligible shareholders to subscribe for new shares in Source BioScience. The Open Offer is to raise up to approximately £1.02m before expenses and to the extent that the Open Offer is not taken up by Qualifying Shareholders, the Board intends to seek subscribers for such shares on substantially the same terms as the Open Offer.

Read more »

Telormedix Receives EU Funding for the Development of a New Treatment for Psoriasis

Bioggio, Switzerland – Telormedix SA, a clinical stage biopharmaceutical company focusing on toll-like receptor 7 (TLR7) small molecules in the treatment of cancer and inflammatory diseases, today announced that it has raised funding from the European Eurostars Programme to coordinate an international research project involving a consortium of companies aimed at developing new formulations of one of the Company’s promising drug candidates, TMX-302, for the treatment of psoriasis. The psoriasis anti-inflammatory treatment project, operating under the acronym PAT, will have a total budget of €1.77 M and will involve consortium partners Biopta, Midatech Biogune, Molecular Profiles and the University Hospital Zurich (USZ).

Read more »

gIcare Pharma Initiates Phase 2a Study of its Lead Product, GIC-1001, in Sedation-Free Analgesia for Colorectal Cancer Screening

Montréal, Québec, Canada – gIcare Pharma Inc today announced the initiation of a phase 2a study of GIC-1001, a novel orally-administered opioid agonist drug candidate to provide sedation-free, colonic analgesia in patients undergoing colonoscopy.

Read more »

Prosensa to Present at Wedbush 2013 Life Sciences Management Access Conference

Leiden, The Netherlands — Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans GCP Schikan, Chief Executive Officer, will present a corporate overview at the Wedbush 2013 Life Sciences Management Access Conference in New York, NY on Tuesday, August 13, 2013 at 1:55pm ET. A live webcast of the presentation can be accessed through the Investor section of the Prosensa corporate website at http://ir.prosensa.eu/events.cfm and will be archived for 90 days.

Read more »

Source BioScience plc Possible Recommended Offer for Vindon Healthcare PLC (“Vindon”)

Nottingham, UK – Further to the announcement regarding the possible offer for Vindon by Source BioScience on 15 July 2013 (the “Possible Offer”), Source BioScience announces that it has acquired further irrevocable undertakings from certain Vindon shareholders, representing a further 22.17 per cent. of the issued and to be issued share capital of Vindon as set out below, to accept its possible offer, if made, at the price of 13.7 pence per Vindon share (the “Possible Offer Price”).  

Read more »

Biotechs and NASDAQ – mutual attraction

Since the start of 2013, the market for IPOs on NASDAQ has been very buoyant.  With little activity over the past few years, it has been a welcome change by many biotech companies that have taken advantage of the opening of the funding window to list on NASDAQ including our client Prosensa Holding N.V.

Read more »

Prosensa Awarded EUR 6 million EU FP7 Research Grant

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it has been awarded a prestigious Framework Programme 7 (FP7) research grant from the European Union to support the ongoing clinical study of the Company’s third novel development candidate, PRO045, for the treatment of Duchenne muscular dystrophy (DMD).

Read more »

Polyphor Achieves First Milestone in Macrocycle Drug Discovery Collaboration with Boehringer Ingelheim

Allschwil, Switzerland − Polyphor, a research-driven pharmaceutical company and leader in the discovery and development of macrocyclic drugs, today announced that Boehringer Ingelheim has decided to enter into the next stage of its drug discovery collaboration with Polyphor. Financial details were not disclosed.
This collaborative project was originally initiated in June 2012 with the objective to discover and develop novel macrocyclic compounds for targets nominated by Boehringer Ingelheim. Following the successful hit identification phase, the parties have now agreed to move forward to generate candidates suitable for pre-clinical development.

Read more »

Clinigen Group to Manage Third Access Program for BTG

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) today announced that Clinigen Global Access Programs (‘Clinigen GAP’) has extended its existing distribution agreement with Protherics Medicines Development Ltd, a BTG International group company (‘BTG’), to exclusively manage a named patient program in 37 European Countries for uridine triacetate for use as an antidote to overexposure to the chemotherapy drug 5-fluorouracil (‘5-FU’). Wellstat Therapeutics Corporation (‘Wellstat’) is seeking approval in the US and Europe for its investigational drug, uridine triacetate, and granted named patient supply rights to BTG in the 37 European Countries in 2012. Uridine triacetate is the third product that BTG has placed under Clinigen GAP’s management.

Read more »

Imperial Innovations' Portfolio Company PolyTherics Merges with Antitope

London, UK – Imperial Innovations Group plc (AIM: IVO, “Innovations” or “the Group”) has led investment into an enlarged biopharmaceuticals group comprising PolyTherics Limited and Antitope Limited. 

Read more »

Clinigen Group plc: Pre-Close Trading Update

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the global specialty pharmaceuticals and services company, today announces its pre-close trading update for the year ended 30 June 2013.

Read more »

Eurofins Panlabs strengthens drug discovery services with GE Healthcare’s Cytiva Cardiomyocytes

Chalfont St Giles, UK – Eurofins Scientific (EUFI.PA), the world leader in food, environment and pharmaceutical products testing, has signed an agreement with GE Healthcare for the exclusive right to offer GE Healthcare’s Cytiva™ Cardiomyocytes for drug discovery and early development cardio toxicity screening services.

Read more »

BioInvent Interim Report

Lund, Sweden – BioInvent International (OMXS:BINV) today announces important events in the second quarter and after the end of the reporting period 1 January – 30 June 2013.

Read more »

Source BioScience issues update regarding funding arrangements for the possible offer for Vindon Healthcare PLC

Nottingham, UK – On 15 July 2013 the Board of Source BioScience (the "Board"), the international diagnostic and genetic analysis services business, announced that it was at an advanced stage of discussions with the board of Vindon Healthcare plc ("Vindon Healthcare"), a leading provider of controlled environment services and products to the pharmaceutical and life sciences sectors in the UK, Ireland, Europe and North America, regarding a possible all cash offer (the "Possible Offer") for the entire issued and to be issued share capital of Vindon Healthcare not already owned by Source BioScience, at a price of 13.7 pence per Vindon Healthcare share (the “Possible Offer Price”).  The Possible Offer Price would value the entire issued and to be issued share capital of Vindon Healthcare at approximately GBP 12.2 million.

Read more »

NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy

Berlin, Germany – NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

Read more »

caprotec bioanalytics and Bayer CropScience Announce Second Collaborative Research Agreement

Berlin, Germany – caprotec bioanalytics GmbH and Bayer CropScience announced today that they have entered a second research collaboration to identify and elucidate a tractable agrochemical target using caprotec’s proprietary Capture Compound Mass Spectrometry technology (CCMS).

Read more »

Imperial Innovations Group plc: Board Change

London, UK – Imperial Innovations Group plc (AIM: IVO, “Innovations” or “the Group”), a leading technology commercialisation and investment group, announces that Susan Searle has stepped down as Chief Executive Officer.  Russ Cummings, Chief Investment Officer and a director since the Group’s flotation in 2006, has become Chief Executive Officer with immediate effect.

Read more »

Source BioScience plc: Possible Offer for Vindon Healthcare plc

Nottingham, UK – The Board of Source BioScience (the “Board”) the international diagnostic and genetic analysis services business, announces that it is at an advanced stage of discussions with the board of Vindon Healthcare, a leading provider of controlled environment services and products to the pharmaceutical and life sciences sectors in the UK, Ireland, Europe and North America, regarding a possible all cash offer (the “Possible Offer”) for the entire issued and to be issued share capital of Vindon Healthcare not already owned by Source BioScience, at a price of 13.7 pence per Vindon Healthcare share (the “Possible Offer Price”).  The Possible Offer would value the entire issued and to be issued share capital of Vindon Healthcare at approximately £12.2 million.

Read more »

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

Lausanne, Switzerland and New York, US − ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

Read more »

Clinigen Group Makes Organizational Changes to Scale-up for Future Business Growth

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) today announced that it has made organizational changes to prepare and support the Group to scale-up in line with its five year growth strategy and support recent organic growth and the integration of two new products in the Specialty Pharmaceuticals business.

Read more »

Prosensa Holding N.V. Announces Closing of Initial Pubilc Offering

Leiden, the Netherlands — Prosensa Holding N.V. (“Prosensa”) announced today the closing of its previously announced initial public offering of 6,900,000 of its ordinary shares at a price of $13.00 per share (including an additional 900,000 ordinary shares pursuant to the exercise of the over-allotment option by the underwriters). The ordinary shares began trading on the Nasdaq Global Market on June 28, 2013 under the symbol “RNA”.

Read more »

BioInvent Receives Clinical Milestone in Partner Program

Lund, Sweden – BioInvent International (OMXS:BINV) today announces that it will receive a milestone payment in connection with a partner’s start of a phase I clinical study using a n-CoDeR® antibody.

Read more »

OncoEthix Closes 18 Million CHF (~US$19 Million) Series B Financing

Lausanne, Switzerland – OncoEthix, the Swiss-based specialist in oncology drug development, announces that it has closed a Series B financing raising 18 Million CHF (~US$19 Million). SV Life Sciences (SVLS) led the financing, joined by new investor Edmond de Rothschild Investment Partners. Existing investors including Index Ventures and Endeavour Vision also participated in the round.

Read more »

Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication

Paris, France – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today it has secured c.€9 million in funding from bpifrance (formerly OSEO) of which €2.8 million is directly attributable to the Company. This grant, awarded through bpifrance’s Strategic Industrial Innovation (ISI) program, will accelerate the clinical and industrial development of the Company’s lead product NBTXR3 in a new indication, liver cancer (hepatocellular carcinoma). Liver cancer is a major health problem that causes one of the greatest number of deaths each year worldwide, c.695,000 deaths per annum.

Read more »

Imperial Innovations Group plc: £30m, 12-year loan to Imperial Innovations from European Investment Bank for healthcare investment

London, UK – Imperial Innovations Group plc (AIM: IVO, “Innovations” or “the Group”) has obtained a loan for a period of 12 years from the European Investment Bank (EIB) to invest in the biotech and therapeutics sectors.

Read more »

BioInvent extends collaboration for the discovery and development of therapeutic antibodies with Mitsubishi Tanabe

Lund, Sweden – BioInvent International AB (OMXS: BINV) today announces that it has signed an extension to its 2009 license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies from BioInvent's n-CoDeR® library. Under the terms of the extension, Mitsubishi Tanabe will continue to have access to BioInvent's discovery and development technology platform for a further two years and can develop up to eight antibody programmes.

Read more »

AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections

Richmond, VA, US, Sydney, Australia and London, UK – AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).

Read more »

Autifony Therapeutics Announces £2.75m Collaboration with Universities of Manchester and Newcastle to Progress a First-in-Class Drug for Schizophrenia

London, UK – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced a collaboration with research groups at the University of Manchester and Newcastle University to develop a novel, first-in-class Kv3 potassium channel modulator for the treatment of schizophrenia. The £2.75 million research collaboration is part-funded by the award of a £1.9 million grant to Autifony and the two Universities, by the UK’s innovation agency, the Technology Strategy Board. The award follows a successful funding application to the Biomedical Catalyst, jointly funded by the Technology Strategy Board and the Medical Research Council.

Read more »

Prosensa Holding B.V. Prices Initial Public Offering

Leiden, the Netherlands — Prosensa Holding B.V. (“Prosensa”) announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $13.00 per share, before underwriting discounts. Prosensa has also granted the underwriters a 30-day option to purchase up to an additional 900,000 ordinary shares to cover over-allotments, if any. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on June 28, 2013 under the symbol “RNA.”

Read more »

College Hill Congratulates Andrew Clark for Winning “Mediscience Commentator of the Year” Award

London: College Hill Life Sciences is pleased to congratulate Andrew Clark from The Times of London for winning the 2013 award for the “Mediscience Commentator of the Year” at the European Mediscience Awards on 20th June 2013 in recognition of his clear and concise commentary on the Life Sciences Sector.

Read more »

Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the National Cancer Institute for development

Paris, France – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the selection of a new product for development, NBTX-IV. It is the second product of the NanoXray pipeline which is designed for systemic administration (intravenous injection). This product has been selected by the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization on the basis of its potential to impact cancer treatment.

Read more »

Imperial Innovations Group: Investment in Psychology Online

London, UK − Imperial Innovations Group plc (AIM: IVO, ‘Innovations’, or ‘the Group’) a leading technology commercialisation and investment company, has invested £0.5m in new portfolio company, PsychologyOnline, a Cambridge-based provider of clinically-proven online cognitive behavioural therapy (CBT) for the treatment of depression.

Read more »

VivaMab and ADC Therapeutics Announce Antibody Licensing Deal for Novel ADC Candidate to Target Hematologic Cancers

San Diego, USA and Lausanne, Switzerland − VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), today announced a licensing deal for a novel antibody against an undisclosed  hematological cancer target.

Read more »

Evaluate Group Report Return to Growth for Pharmaceutical Sector: Surge in Drug Approvals, R&D Productivity and Investor Confidence to Drive Expansion Through 2018

London, UK and Boston, USA — According to the newly-released World Preview report from market intelligence firm Evaluate Ltd, the worst of the patent cliff is behind us. While the pharmaceutical industry is feeling the effects of last year’s decline in performance — with worldwide prescription drug sales down 1.6% — sales are forecast to   start growing slowly in 2013 and then steadily increase, reaching $895 billion by 2018, according to Evaluate’s report, “World Preview 2013, Outlook to 2018: Returning to Growth.”

Read more »

Prof Marc Van Montagu, Chairman of FuturaGene’s Scientific Advisory Board, Receives the World Food Prize 2013

Sao Paulo, Brazil – FuturaGene, a world leader in the enhancement of yield and sustainability of woody crops for plantation forestry, biopower and biofuel markets, today announced that the chairman of its Scientific Advisory Board, Professor Marc Van Montagu, is a joint recipient of this year’s World Food Prize. The award is shared between three distinguished international scientists for their ground-breaking research in the field of agricultural biotechnology. Prof Van Montagu and his colleagues at Ghent University were the first to design a technology for the stable transfer of genes into plants. Their findings paved the way for the development of new genetic lines of crops expressing beneficial traits.

Read more »

Clinigen Group Extends Agreement to Exclusively Supply Clinical Trials with Accord Healthcare’s EU Oncology Products

Burton-on-Trent, UK  – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) today announced that Clinigen Clinical Trial Supply (‘CTS’) has extended its exclusive clinical trial distribution agreement with Accord Healthcare (‘Accord’), a wholly-owned marketing subsidiary of Intas Pharmaceuticals, to supply clinical trials with Accord’s European injectable oncology drug portfolio for a further two years.

Read more »

Source BioScience launches new Overnight Service for DNA sequencing for Scotland

Nottingham, UK – Source BioScience plc (“Source BioScience”) has extended the reach of its rapid, market leading DNA sequencing and data analysis service in the UK with today’s launch of its Overnight Service in Scotland.

Read more »

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead

Copenhagen, Denmark and Lausanne, Switzerland – Genmab A/S (OMX: GEN) and ADC Therapeutics, announced today an agreement to develop a new antibody-drug conjugate (ADC) product combining Genmab’s HuMax-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. The Companies have been conducting in vitro and in vivo studies since 2012 to investigate different warhead and linker combinations with HuMax-TAC, and now have the product ready for pre-IND preclinical development.  The product will be developed for multiple cancer indications.

Read more »

Evaluate Report to Examine Life After the Patent Cliff, Provides Analysis on Pharmaceutical and Biotech Markets and Consensus Forecasts to 2018

London, UK and Boston, USA — Patent expirations in 2012 have put the industry through an unprecedented decline in worldwide prescription drug sales in 2012. Now that the pharmaceutical industry has faced the biggest patent cliff it has ever seen, Evaluate Ltd. will examine its effects and what the industry can expect through 2018 in its upcoming annual World Preview report. Evaluate will release the report, which is based on EvaluatePharma® data, on Monday, June 24 in conjunction with the DIA 2013 49th Annual Meeting in Boston, MA.

Read more »

Digital Health Poised to Change the Face of Healthcare

London, UK – “Society is changing so quickly, we are all now technology consumers and we see this mapping onto healthcare,” heralded Simon Cook, CEO of DFJ Esprit, speaker and panellist at the Digital Health Forum 2013 (DHF13) held in London on 11 June. The speakers and panellists agreed that in order to bring healthcare to the masses digital health will play a crucial role.

Read more »

Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3

Paris, France – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that its lead compound NBTXR3 has received authorization from the French Medicine Agency, ANSM[1], to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment center. This represents a second indication for NBTXR3 which is also in clinical trials for soft tissue sarcoma.

Read more »

Dezima Pharma Appoints Seasoned New CEO

Naarden, The Netherlands – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that it has appointed Rob de Ree as its new Chief Executive Officer.

Read more »

Polyphor Attracts Senior Pharma Professionals to Strengthen its Board of Directors

Allschwil, Switzerland − Polyphor Ltd, a research-driven pharmaceutical company and leader in the discovery and development of macrocyclic drugs, today announced that its shareholders elected four new Members of the Company’s Board of Directors, including two senior Pharma professionals, Jerry Karabelas and Jean-Jacques Garaud, capital markets specialist Bernard Bollag, and Polyphor CEO Jean-Pierre Obrecht.

Read more »

Top 10 Highlights of BIO 2013

BIO International Congress, April 22-25 2013, Chicago, USA

In its twentieth year, BIO is the biggest event in the life science sector. Senior Account Director Stefanie Bacher and Junior Account Director Dr Anastasios Koutsos represented College Hill at the conference, reporting a whirlwind experience, which could be summarized under the motto “think big”. An exhibit hall floor of 2,670,000 sq ft alone, the size of four football fields, 15,000 attendees from all over the world and the amount of energy was impressive to say the least. Recapping information from 125+breakout sessions, 800+ speeches, 6 super sessions and a couple of keynotes seems like a mission impossible. After digesting the event, here are their ‘top 10’ highlights... 

Read more »

Digital Health Forum 2013 (DHF13) Announces its Top Speaker Line-up

London, UK – Connect Digital Health, organisers of the forthcoming Digital Health Forum 2013 (DHF13) to be held in London on 11 June, has announced the top speaker line-up for the event, including leading journalists, authors, business strategists and successful entrepreneurs.

Read more »

College Hill Life Sciences Secures a Clutch of New Mandates

London, Manchester, Munich, Boston, Sydney, Melbourne: The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, continues to expand its portfolio with 11 additional client wins across both the private and public sectors in Europe, the USA and Australasia. New clients’ mandates span the Consultancy’s offering from fully retained services to branding and IR/PR projects.

Read more »

College Hill and SwedenBIO Partner to Promote Nordic Life Science Days

London: College Hill Life Sciences, part of the international business communications consultancy College Group, is pleased to have secured a communications partnership with SwedenBIO. SwedenBIO are the organisers of the inaugural Nordic Life Science Days, an extended version of the annual Life Science Investment Day Scandinavia, which will be held at Stockholm Waterfront, 14-15 October 2013 in collaboration with its sister organisations in Denmark, Finland and Norway.

Read more »

Autifony Therapeutics Initiates Phase I Study for Lead Product, AUT00063, for the Treatment of Hearing Loss and Tinnitus and Tops Up Series A Financing with Further £5.5 million Investment

London, UK −  Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced the start of a Phase I clinical study of the novel, first-in-class Kv3 potassium channel modulator, AUT00063.

Read more »

OGT Launches Pre-implantation Genetic Screening Array Aimed at Improving the Chances of Successful IVF

Oxford, UK –  Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has announced the launch of a new pre-implantation genetic screening (PGS) array aimed at improving the chances of successful in-vitro fertilisation (IVF).

Read more »

Imperial Innovations: Autifony Initiates Phase I Trial for Treatment of Hearing Loss and Tinnitus

London, UK −  Imperial Innovations Group plc (AIM: IVO, ‘Innovations’, or ‘the Group’) a leading technology commercialisation and investment company, announces that its portfolio company, Autifony Therapeutics has initiated a Phase I clinical study of AUT00063, its lead product for the treatment of hearing disorders.

Read more »

Ockham Biotech Overturns Vectura's Challenge to Secure European Patent Rights for Inhaled Heparin in the Treatment of COPD

Swanwick, UK – Ockham Biotech Ltd (‘Ockham’), a company specialising in the research, development and commercialisation of new therapies for respiratory disorders, is pleased to announce that its European patent covering the use of inhaled heparin for the treatment of patients with chronic obstructive pulmonary disease (COPD) and mucus hypersecretion has been restored, following its grant in 2008 and subsequent revocation in 2011.

Read more »

Nanobiotix’s NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma

Paris, France  – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-based product, NBTXR3, in patients with Soft Tissue Sarcoma (STS).

Read more »

Uscom to Acquire New Zealand-based Pulsecor and New Blood Pressure Products

Sydney, Australia – Uscom Limited (ASX: UCM) today signed a deed to acquire all assets of Pulsecor Limited. Pulsecor Limited is a New Zealand company which has developed novel non-invasive central blood pressure measurement methods pioneered at the Weill Cornell Medical College in New York. Under terms of the deed and on completion Uscom will acquire all Pulsecor technology, products and 34 global patents and patent applications related to measurement and monitoring of blood pressure in exchange for 5 million fully paid ordinary Uscom shares.

Read more »

Atopix Therapeutics awarded Biomedical Catalyst grant to study an innovative anti-allergic approach to the treatment of atopic dermatitis

Abingdon UK - Atopix Therapeutics Ltd (“Atopix”), a biopharmaceutical company developing a novel class of anti-allergic medicines, has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).

Read more »

FuturaGene enters agreement with Danforth Center to provide plant yield-enhancing technology to developing countries

Sao Paulo, Brazil – FuturaGene, a world leader in the enhancement of yield and sustainability of woody crops for plantation forestry, biopower and biofuel markets, has entered into an agreement with the Donald Danforth Plant Science Center, world’s largest independent nonprofit research institute focused on plant science, which will see FuturaGene’s plant yield-enhancing technology tested on staple crops grown by farmers in Asia, Africa and Brazil.

Read more »

College Hill congratulates this year's nominees for the European Mediscience Awards

College Hill Life Sciences congratulates all the nominees shortlisted for the European Mediscience Awards 2013, especially those individuals and companies in the category, Commentator of the Year, of which College Hill is the sponsor.

Of College Hill Life Sciences own clients, congratulations go to Clinigen Group (Transaction of the year, Emerging Company), Imperial Innovations (Most Significant Contribution), and Oxford Gene Technology (Emerging Star).

Read more »

College Hill Congratulates the Nominees for the European Mediscience Awards 2013

London: College Hill Life Sciences congratulates all the nominees shortlisted for the European Mediscience Awards 2013, especially those individuals and companies in the category, Commentator of the Year, of which College Hill is the sponsor.

Read more »

OGT launches ground-breaking 58-gene tumour profiling service to predict patient response to cancer treatment

Oxford, UK – Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has furthered its commitment to fighting cancer with the launch of a new solid tumour profiling next-generation sequencing service to advance vital research into personalised cancer care. OGT is the first commercial facility in the UK to offer this service.

Read more »

ugichem receives €2.25 million funding for antisense drug platform

Innsbruck, Austria – ugichem GmbH, developer of a novel antisense drug platform, has raised €2.25 million from public and private investors to advance preclinical Ugimer® drug development for immune-mediated inflammatory diseases (IMID). ugichem was awarded a grant of €850,000 by Austria’s Research Promotion Agency FFG and received an equity financing of €1.4 million from existing investors.

Read more »

BioInvent Recruits Michael Oredsson As New CEO

Lund, Sweden − BioInvent International AB (STO: BINV) announces today that the Company's Board of Directors has appointed Michael Oredsson as new President and CEO. He will take office within six months.

Read more »

Phagenesis Expands Series B Financing to $17 million

Manchester, UK − Phagenesis, the world’s leading company in the treatment of dysphagia, has expanded its Series B financing to $17m.

Read more »

Novo A/S acquires Xellia Pharmaceuticals for US$ 700 million

Oslo, Norway and Copenhagen, Denmark – Xellia Pharmaceuticals (“Xellia”), a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, announced today that Novo A/S (“Novo”), the holding company of the Novo Group, has purchased all shares of the group for approximately US$ 700 million from 3i and other current shareholders. As a consequence of the transaction, Xellia will revert to Danish ownership with headquarters in Copenhagen, Denmark.

Read more »

Competition Launched to Select the Hottest Five Emerging Companies in the Digital Health Space

London, UK – Connect Digital Health, organisers of the forthcoming Digital Health Forum 2013 (DHF13) to be held in London on 11 June, has launched its ‘Hot 5’ competition. The competition is open to emerging digital health companies, with the five winners gaining free access to the conference to pitch their business ideas to leading digital health investors.

Read more »

Source BioScience Interim Management Statement

Nottingham, UK – Source BioScience plc (LSE: SBS), the international diagnostic and genetic analysis services business, today publishes its Interim Management Statement for the year to date.
 

Read more »

Nanobiotix revenue for the 1st quarter of 2013

Paris, France – Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2013.

Read more »

e-Therapeutics’ Preliminary Results for the Year Ended 31 January 2013

Oxford & Newcastle, UK – e-Therapeutics plc (“e-Therapeutics”; AIM: ETX), the drug discovery and development company, today announces its preliminary results for the year ended 31 January 2013. 

Read more »

OGT Marks World Lupus Day with Announcement of Novel Biomarker Panel to Support Earlier SLE Diagnosis

Oxford, UK –  Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has today announced the development of a novel autoantibody biomarker panel for improved diagnosis of systemic lupus erythematosus (SLE).

Read more »

Cell Medica Announces Treatment of First Pediatric Patient in Early Stage Clinical Trial of Cytovir ADV

London, UK – Cell Medica today announced the treatment of the first patient in the ASPIRE Trial, an early stage Phase I/II clinical study investigating the safety and efficacy of CytovirTM ADV for the treatment of adenovirus infections in immunosuppressed pediatric patients following bone marrow transplantation.

Read more »

Sydney Based Cellmid Acquires Japanese Advangen

Sydney, Australia - Cellmid Limited (ASX: CDY) today announced that it will acquire Advangen Inc., Japan (Advangen), the Company that owns the FGF-5 inhibitor hair growth technology. Cellmid already markets the successful évolis® hair product range, which was originally derived from this technology, outside of Japan on behalf of Advangen. This is a highly strategic acquisition that will significantly increase Cellmid’s revenues in the short to medium term.

Read more »

Imperial Innovations Group plc: Cell Medica Treats First Paediatric Patient in Clinical Trial of Cytovir ADV

London, UK - Imperial Innovations Group plc (AIM: IVO, ‘Innovations’ or ‘the Group’), a leading technology commercialisation and investment group, announces that portfolio company Cell Medica, a biotechnology company developing cellular therapeutics for infectious diseases and cancer has commenced treatment of the first patient in its ASPIRE Trial.

Read more »

Source BioScience plc: Acquisition of Inverclyde Biologicals Limited

Nottingham, UK − Source BioScience plc (LSE: SBS), the international diagnostic and genetic analysis services business, announces the acquisition of the entire issued share capital of Inverclyde Biologicals Limited (‘Inverclyde Biologicals’), Motherwell, Scotland for a total consideration of £1.6 million payable in cash.

Read more »

College Hill Enters Media Partnership with Connect Digital Health to Promote Digital Health Forum DHF13

London: College Hill Life Sciences, part of the international business communications consultancy College Group, announces that it has been selected as communications partner by Connect Digital Health, the organisers of the Digital Health Forum for Investors & Industry 2013 (DHF13), to be held at the Royal Society of Medicine, London on 11 June 2013.

Read more »

Nanobiotix 2012 Annual Results

Paris, France – Nanobiotix (Euronext: NANO–ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its audited consolidated results for the 2012 fiscal year closed on December 31.

Read more »

SensiumVitals® Pilot Study Demonstrates Significant Improved Patient Care and Hospital Cost Savings

Abingdon, UK − Toumaz Limited (AIM: TMZ), a pioneer in low cost, ultra-low power wireless communications technology, announces the results of its pilot study for its SensiumVitals® disposable wireless vital signs monitoring solution. The study exceeded expectations with SensiumVitals® detecting all patients who experienced deterioration in their condition between routine ward observation rounds, preventing more serious clinical problems and saving an average of $9,004 per patient, per stay.

Read more »

Digital Health Forum 2013 (DHF13), Royal Society of Medicine, London, UK, 11 June 2013

London, UK – Connect Digital Health, an industry organisation dedicated to promoting the development of digital tools to improve healthcare outcomes, has drawn together leaders in the digital health industry to launch a new invitation-only conference, Digital Health Forum 2013 (DHF13), as a new platform for investors and industry to meet to create new partnerships. Details of the programme and registration can be found at www.dhf13.com.

Read more »

BioGasol ApS Delivers its First Commercial Pretreatment System to Sweetwater Energy

Copenhagen, Denmark – BioGasol ApS, the renewable energy company, today announced the delivery of its first commercial biomass pretreatment system to US-based Sweetwater Energy, Inc. The cellulosic sugar producer will use the unit, a Carbofrac™ 10, in its demonstration facility to produce pretreated biomass for use in downstream processes.

Read more »

Forbion Capital Partners co-leads €15 Million Series A Financing for Allecra Therapeutics

Munich, Germany and Naarden, The Netherlands – Forbion Capital Partners, the Dutch life sciences venture capital firm, today announced that it has co-led the €15 million Series A financing round for Allecra Therapeutics GmbH, together with Edmond de Rothschild Investment Partners. EMBL Ventures was also part of the syndicate.

Read more »

College Hill Award Finalist for its Communications Campaign in Support of Clinigen Group AIM Listing

London: College Hill Life Sciences, part of the international business communications consultancy College Group, has been short listed as a finalist by the Communicate Magazine Corporate & Financial Awards 2013 in the category of 'Best M&A/Other Transaction Communications' for its campaign in support of the listing on the London Stock Exchange Alternative Investment Market by its client Clinigen Group plc.

Read more »

AmpliPhi Establishes Collaboration with Intrexon

Richmond, VA, and Germantown, MD, USA – AmpliPhi BioSciences Corp. (OTC: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, and Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, today announced the formation of an exclusive channel collaboration (“ECC”) to develop new bacteriophage-based therapies to target specific antibiotic resistant infections, some of the most widespread and deadly types of infections.

Read more »

Recruitment in World's Largest Interventional Oncology Study Completed

Sydney, Australia – Australian-based global oncology company, Sirtex Medical Limited (ASX: SRX), has announced the completion of patient recruitment for its global SIRFLOX clinical study which is aimed at expanding the clinical use of its SIR-spheres®  microspheres targeted radiation therapy from a last line medical treatment to a standard first-line oncology therapy.

Read more »

DySIS Medical receives £7.4m of additional funding

Edinburgh, UK – DySIS Medical Ltd, a medical devices company active within women’s health, today announces the completion of a £7.4 million (gross) fundraising.

Read more »

Mesoblast Chief Executive Honoured at the Vatican with Inaugural Pontifical Award for Innovation

Melbourne, Australia – Regenerative medicine company Mesoblast Limited (ASX:MSB, USOTC:MBLTY) is pleased to announce that its Chief Executive Professor Silviu Itescu today received the inaugural ‘Key Innovation Award 2013’ from the Pontifical Council for Culture and The Stem for Life Foundation. This unique recognition was announced during the Second International Vatican Adult Stem Cell Conference currently being held in Vatican City.

Read more »

Karus Therapeutics Appoints Scientific Advisory Board and Announces Move to New Oxford Facilities

Oxford, UK – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced the appointment of its scientific advisory board (SAB), which brings together world-leading expertise in target biology and drug research and development. The appointment of Karus’s SAB reflects the Company’s recent expansion and move to fully-integrated research and office facilities near Oxford.

Read more »

Spirogen and BioAtla present positive data on next-generation warheads in ADCs against cancer

London, UK and San Diego, USA – Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC. Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

Read more »

MISSION Co-Founder and CSO becomes an Associate Faculty Member at the Wellcome Trust Sanger Institute

Cambridge, UK – MISSION Therapeutics (“MISSION”), the company focused on the discovery and development of modulators of deubiquitylating enzymes (DUBs) for the treatment of cancer, is pleased to announce the recent appointment of the Company’s co-founder and Chief Scientific Officer, Professor Steve Jackson as Associate Faculty Member at the prestigious Wellcome Trust Sanger Institute.  Professor Jackson is a Fellow of both the Royal Society and the UK Academy of Medical Sciences, and since 1995 has held the Frederick James Quick Chair of Biology at the University of Cambridge, a post which he currently combines with Head of the Cancer Research UK Laboratories at the Gurdon Institute, Cambridge.

Read more »

BioInvent Presents Positive Data for BI-505 at International Myeloma Congress

Lund, Sweden – BioInvent International AB (OMXS:BINV) announce that the previously communicated positive results from a phase I trial of BI-505 is presented today at The International Myeloma Workshop in Kyoto, Japan. At the same meeting, preclinical data is also presented which demonstrate significantly enhanced efficacy when approved myeloma drugs are combined with BI-505. BI-505 is a human antibody directed against ICAM-1 and is developed for the treatment of multiple myeloma.

Read more »

Dr. Laurent Levy, CEO of Nanobiotix, receives the UB Entrepreneurship Award from the University at Buffalo, SUNY

Paris, France – Nanobiotix (Euronext: NANO), the oncology focused nanomedicine company, announces that its CEO and co-founder, Dr. Laurent Levy, has received the UB Entrepreneurship Award at the Annual Inventors and Entrepreneurs Reception on March 25 2013 at the University at Buffalo (UB), Buffalo, NY, USA, which he attended as guest of honor.

Read more »

College Hill Clients’ First and Fifth Largest Capital Raisings in Life Sciences in 2013 to Date

London, Manchester, Munich, Boston, Sydney, Melbourne: Earlier this month College Hill Life Sciences’ ASX-listed client Mesoblast closed AU$170 million (US$176 million) in a private placing with institutional investors. Based on BioWorld’s Insight report issued early March, this is the largest Life Sciences private financing of a public company globally of 2013, just pipping the amounts raised by US-based Ironwood Pharmaceuticals (NASDAQ) and OPKO Health Inc. (NYSE) in January. AIM-listed client, e-Therapeutics, which raised £40 million (US$63m) from an issue of new shares in February, would place it as the fifth largest financing according to figures in the BioWorld report.

Read more »

College Hill Clients’ 1st and 5th Largest Capital Raisings in Life Sciences in 2013 to Date

In March College Hill Life Sciences’ ASX-listed client Mesoblast closed AU$170 million (US$176 million) in a private placing with institutional investors. Based on BioWorld’s Insight report issued early March, this is the largest Life Sciences private financing of a public company globally of 2013, just pipping the amounts raised by US-based Ironwood Pharmaceuticals (NASDAQ) and OPKO Health Inc. (NYSE) in January. AIM-listed client, e-Therapeutics, which raised £40 million (US$63m) from an issue of new shares in February, would place it as the fifth largest financing according to figures in the BioWorld report.

Read more »

Clinigen Group plc acquires oncology support therapy Cardioxane® from a world-leading pharmaceutical company

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (LSE: CLIN) (AIM: CLIN) today announced the acquisition of Cardioxane® (dexrazoxane) from Novartis for US$33 million in cash, payable in two tranches. Under the terms of the agreement, Clinigen will assume responsibility for manufacturing, registration, distribution, and commercialization of the product in countries where current marketing authorizations exist, including key European, Asian and Latin American territories.

Read more »

Imperial Innovations HY results - Major growth potential in key portfolio companies

London, UK – Imperial Innovations Group plc (AIM: IVO, “Innovations”, “the Group”), a leading technology commercialisation and investment group, has published its results for the six months ended 31 January 2013.

Read more »

Dr Oern Stuge Appointed Chairman of Phagenesis

Manchester, UK – Phagenesis, the world’s leading company in the treatment of dysphagia, has appointed Dr Oern Stuge, former senior executive at Medtronic and Abbott Laboratories, as Chairman.

Read more »

Source BioScience Preliminary Results for Year Ended 31 December 2012

Nottingham, UK – Source BioScience plc (LSE: SBS), the international diagnostic and genetic analysis services business announces its unaudited preliminary results for the year ended 31 December 2012.

Read more »

Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference

Paris, France – Nanobiotix (Euronext: NANO), the oncology focused nanomedicine company, announces that its co-founder and CEO, Laurent Levy, has been invited to give a Company Presentation at the 20th Annual Future Leaders in the Biotech Industry Conference in New York.

Read more »

Biotechnology Business Leader Appointed CEO of Australian Nobel Prize Winner’s Company

Sydney, Australia – Australian drug delivery system company Ondek Limited today announced the appointment of Dr Jenny Harry as Chief Executive Officer.

Read more »

Vaxxas Recognized as 2013 BioSpectrum Asia-Pacific Emerging Company of the Year

Brisbane, Australia – Vaxxas, a biotechnology company commercializing a novel vaccine-delivery platform that activates immunological cells immediately below the surface of the skin, announced today it has received the BioSpectrum Asia-Pacific Emerging Company of the Year Award.  The award recognizes Vaxxas for the potential of its needle-free Nanopatch™ platform to enhance delivery efficiency and improve effectiveness of a wide range of vaccines.

Read more »

Mesoblast Completes A$170m Private Placement

Melbourne, Australia – Regenerative medicine company Mesoblast Limited (ASX:MSB, USOTC:MBLTY) today announced that it has completed a private placement of its shares, raising A$170 million.  Mesoblast now has cash reserves of approximately A$332 million.

Read more »

OGT granted licence by The Institute of Cancer Research, London, to develop and commercialise prostate cancer biomarker panel

Oxford, UK – Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, announced today that it has been granted a licence by The Institute of Cancer Research (ICR), London, to further develop and commercialise a new panel of diagnostic and prognostic microRNA biomarkers for prostate cancer. The agreement follows a three-year collaboration between OGT and the ICR resulting in the joint discovery of the microRNA biomarkers. These markers have wide-ranging potential applications in diagnosis, prognosis, treatment planning and patient monitoring.

Read more »

Celtic Therapeutics Rebrands as Auven Therapeutics

US Virgin Islands, New York, USA and Lausanne, Switzerland – Celtic Therapeutics Management L.L.L.P. (Celtic Therapeutics), the global private equity company focused on acquiring novel, life-saving and quality of life-enhancing products and accelerating the development of these products, has announced a name change to Auven Therapeutics Management L.L.L.P (Auven Therapeutics) effective from March 11, 2013.  The name change was made in order to overcome confusion related to other Celtic entities, which are not part of Auven Therapeutics.

Read more »

Telormedix enrols first patient for Phase II in bladder cancer

Bioggio, Switzerland – Telormedix, a clinical stage biopharmaceutical company focusing on toll-like receptor 7 (TLR7) small molecules in the treatment of cancer and inflammatory diseases, today announced that it has recruited the first patient in a Phase II trial of its lead product TMX-101, a TLR-7 agonist, in carcinoma in situ (CIS) in the bladder.

Read more »

Clinigen and Theravance Announce Exclusive Commercialization Agreement in the EU for VIBATIV® (telavancin)

Burton-on-Trent, UK and South San Francisco, USA – Clinigen Group plc (LSE: CLIN) (AIM: CLIN)  and Theravance, Inc. (NASDAQ: THRX) today announced that they have entered into an exclusive commercialization agreement in the European Union (EU) and certain other countries located in Europe for VIBATIV® (telavancin) for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable. VIBATIV® is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as MRSA.

Read more »

Polyphor reports successful Phase I results for its Pseudomonas selective antibiotic POL7080

Allschwil, Switzerland – Polyphor Ltd today announced the successful completion of a Phase I clinical trial demonstrating the clinical safety and tolerability of its Pseudomonas specific antibiotic POL7080. POL7080 holds great promise for the treatment of bacterial infections caused by multi-drug resistant Pseudomonas bacteria, one of the most clinically relevant pathogens. Some of these bacteria have become resistant to almost all commercially available antibiotics. As POL7080 kills Pseudomonas bacteria by a novel mode of action it can overcome such resistance and therefore has the potential to offer new treatment options for serious and life-threatening infections.

Read more »

Clinical Network Services (CNS) appoints leading toxicologist Douglas Francis to BioDesk

Brisbane, Australia – Clinical Network Services (CNS), an Australian based CRO offering integrated development services in the planning, implementation and delivery of Phase 1 and 2 trials, today announced that it has appointed ex-Therapeutic Goods Administration (TGA) toxicologist, Dr Douglas Francis, as Senior Regulatory Toxicologist to the Company’s BioDesk product development planning and regulatory affairs service.

Read more »

Dezima Pharma raises €14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001

Naarden, The Netherlands – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that is has raised a total of €14.2m ($18.6m) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995) and to develop additional earlier-stage dyslipidemia assets.

Read more »

Winners of GE Healthcare 2012 Cell Imaging Competition announced

Chalfont St Giles, UK – GE Healthcare Life Sciences today announced Jane Stout, from the United States, Anushree Balachandran from Australia and Markus Posch from the UK as  the winners of the GE Healthcare 2012 Cell Imaging Competition.  With over 15,000 votes cast in a public vote, the winners can now look forward to seeing their prize-winning cellular images displayed in Times Square, New York on NBC Universal’s HD screen at a special event on April 19-21, 2013.

Read more »

Prosensa Receives Rare Disease Company Award from EURORDIS

Leiden, The Netherlands – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, received the ‘Company Award’ at the EURORDIS Black Pearl Gala Dinner in Brussels last night.

Read more »

MISSION Therapeutics announces Biomedical Catalyst Feasibility award to tackle drug-resistant ovarian cancer

Cambridge, UK – MISSION Therapeutics (“MISSION”), the company focused on the discovery and development of modulators of deubiquitylating enzymes (DUBs) for the treatment of cancer, has been granted a Biomedical Catalyst Feasibility Award by the Technology Strategy Board to support the identification of DUBs required for the survival of drug-resistant ovarian cancers.

Read more »

Clinigen Group plc Announces Interim Results for the Six Months Ended 31 December 2012

Burton-on-Trent, UK – Clinigen Group plc (AIM: CLIN, “Clinigen” or “the Group”), the global specialty pharmaceuticals and pharmaceutical services business, has today published its maiden half year results for the six months ended 31 December 2012.

Read more »

OGT Expands Commitment to Improved Cancer Profiling with CCMC Agreement

Oxford, UK –  Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, announced today that it has signed a licence agreement with the Cancer Cytogenomics Microarray Consortium (CCMC) to design a whole genome, cancer-specific microarray.

Read more »

Xellia Enters 4 Year Collaboration to Develop New Antibiotics to Combat Multi-Drug Resistant Bacteria

Oslo, Norway and Copenhagen, Denmark – Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria.

Read more »

York Teaching Hospital Signs Up BD FocalPoint™ and Renews £1.3m Cervical Cancer Screening Contract

Nottingham, UK – Source BioScience (LSE: SBS), the international diagnostics and genetic analysis business, announces that, following a competitive tender process, York Teaching Hospital NHS Foundation Trust (‘York’) has renewed its contract for liquid based cytology (‘LBC’).  York has also committed to implementing Source BioScience’s automated cervical cancer screening BD FocalPoint™ technology. The agreement is worth a total of £1.3 million over three years and will commence on 1 April 2013.

Read more »

Ablynx and Spirogen enter into a research collaboration to evaluate the potential of novel toxin-nanobody drug conjugates in cancer

Ghent, Belgium and London, UK – Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

 

Read more »

Imperial Innovations Group plc - Circassia’s cat allergy treatment shows sustained symptom improvement

London, UK – Imperial Innovations Group plc (AIM: IVO, ‘Innovations’ or ‘the Group’), a leading technology commercialisation and investment group, announces that portfolio company Circassia, the speciality biopharmaceutical company focused on allergy, has seen strong results from its follow up phase II clinical trial.

Read more »

Lab21 and IntegraGen partner to develop new colorectal cancer diagnostic

Cambridge, UK – Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

Read more »

BioInvent Financial Statement – 1 January to 31 December 2012

Key points:

  • Focus on cancer
  • Important events in the fourth quarter and after the end of the reporting period
  • Key financial points
Read more »

Promising pre-clinical data in Cystic Fibrosis for ProtAffin AG’s PA401 to be presented at ATS, Philadelphia, 17-22 May 2013

Graz, Austria and London - ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for inflammation, respiratory disease and oncology, today announced that a collaboration with a leading European centre for the study of cystic fibrosis has generated promising pre-clinical results for the company’s lead anti-inflammatory product, PA401.

Read more »

College Hill Life Sciences Adds New Clients to its Portfolio

The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, has continued to add to its portfolio of clients with six new client wins to date in 2013 from across both Europe and Australia. New clients include both private and listed companies, with mandates ranging from fully retained services to branding and IR/PR projects.

Read more »

College Hill Life Sciences Further Grows its Portfolio of New Clients

London, Manchester, Munich, Boston, Sydney, Melbourne: The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, has continued to add to its portfolio of clients with six new client wins to date in 2013 from across both Europe and Australia. New clients include both private and listed companies, with mandates ranging from fully retained services to branding and IR/PR projects.

Read more »

PolyActiva Raises AUD$9.2M in Series B Venture Funding

Melbourne, Australia – PolyActiva announced today that it has raised AUD $9.2 Million in a Series B financing round from a consortium of investors including the Medical Research Commercialisation Fund (MRCF) and Brandon Biosciences Fund 1 (BBF1) (both managed by Brandon Capital), Yuuwa Capital and additional participation from angel investors.

Read more »

College Hill Sponsors the European Mediscience Awards Event for the 5th Year

London: College Hill Life Sciences, part of the international business communications consultancy, College Group announces that it is the sponsor for the "Mediscience commentator of the year" at the European Mediscience Awards on 20th June 2013.  This will be the 5th year College Hill has sponsored the awards.

Read more »

Helmedix Launched with Start-up Investment from the MRCF to Develop Potential Treatment for Autoimmune Disease

Sydney, Australia − Helmedix Pty Ltd, an early stage biopharmaceutical company developing novel therapies for autoimmune and inflammatory diseases such as rheumatoid arthritis, colitis, psoriasis and multiple sclerosis, was launched today with start-up financing from Australia’s Medical Research Commercialisation Fund (MRCF).

Read more »

FDA Agreement on Mesoblast’s Use of Singapore Manufacturing Facility for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells

Melbourne, Australia − Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) today announced that United States Food and Drug Administration (FDA) is in agreement for Mesoblast to supply its proprietary Mesenchymal Precursor Cells (MPCs) for clinical trials in the United States under Investigational New Drug (IND) protocols, from Lonza's contract manufacturing facility in Singapore, in addition to its United States facility.

Read more »

Nanobiotix Appoints Dr. Alain Herrera to the Supervisory Board

Paris, France, February 13, 2013 − Nanobiotix (Euronext: NANO / ISIN: FR0011341205), the oncology focused nanomedicine company, announced today that Dr. Alain Herrera joins its Supervisory Board, succeeding Thierry Chopin and Isabelle Bou Antoun in their roles, as part of a planned Supervisory Board succession.

Read more »

Mireven Announces Positive In Vitro Results for miRNA-7-5p in Melanoma

Perth, Western Australia – MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, today announced the publication in the journal Biochemical and Biophysical Research Communications of an in vitro study where the microRNA “miR-7-5p” significantly inhibited the migration and invasion of metastatic melanoma cells.

Read more »

e-Therapeutics to Raise £40 Million to Advance Lead Cancer Drug and Exploit Network Pharmacology Platform

Oxford and Newcastle, UK – Drug discovery and development company e-Therapeutics plc (AIM: ETX) proposes to raise GBP 40 million (approximately GBP 39 million net) through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4% to the closing mid-market price on the last dealing day before this announcement. Irrevocable undertakings of support have been received from shareholders representing approximately 86% of the Company’s equity in advance of a general meeting where approval for the issue will be sought.

Read more »

Mesoblast Reports Half-Year 2013 Financial Results

Melbourne, Australia – Mesoblast Limited (ASX:MSB; OTC ADR:MBLTY) today provided its half-year 2013 financial results, as well as a strategic update on the key areas of product development for its Mesenchymal Precursor Cell (MPC) platform technology, particularly in the fields of inflammation and immunity.
Mesoblast Chief Executive Professor Silviu Itescu said: “Our strong cash position enables us to pursue our key areas of MPC product development in parallel in order to most efficiently bring our products to market, either on our own or with strategic distribution partners.”

Read more »

Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs

Leiden, The Netherlands – Prosensa Therapeutics, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced the appointment of Larry Bell, M.D. as its Vice President of Regulatory Affairs. Dr. Bell will be based in the USA.

Read more »

Celtic Pharma Welcomes the Results of the Sale Process of Inspiration Biopharmaceutical’s Hemophilia Assets to Cangene Corporation

Bermuda, London and New York – Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") records today's announcement by Inspiration Biopharmaceuticals ("Inspiration") that it has successfully concluded the sale of its hemophilia product portfolio for an aggregate consideration that could exceed $1 billion.  Celtic Pharma holds a substantial minority stake in Inspiration, and will participate in the transaction proceeds in accordance with an agreement reached between Ipsen as Debtor-in-Possession and the non-Ipsen stakeholders.

Read more »

Key Mesenchymal Precursor Cell Patents Granted in United States and China

Melbourne, Australia – Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted three key new patents by the United States Patent and Trade Mark Office (USPTO) and the State Intellectual Property Office of the People’s Republic of China. These patents deliver major commercial advantages and offer long term protection in these territories for the company’s products based on its proprietary Mesenchymal Precursor Cell (MPC) adult stem cell technology platform.

Read more »

College Hill Life Sciences Welcomes New Team Member to its Munich Team

Munich: College Hill, part of the international business communications consultancy, College Group, is pleased to announce the appointment of Cora Kaiser to its Life Sciences team. She joins the Munich office as Account Executive.

Read more »

AmpliPhi Receives Notice of Allowance on Key Patent for its Bacteriophage Therapy to Treat Drug-resistant Biofilm-based Infections

Richmond, USA, London, UK and Sydney, Australia  − AmpliPhi Biosciences Corporation [APHB.PK] (“Ampliphi”), the anti-infective company focused on developing phage-based therapies to combat the growing threat of antibiotic-resistant infection, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/333,684 entitled “Bacteriophage-Containing Therapeutic Agents”.

Read more »

OncoEthix Doses First Patient in its Phase I Trial of OTX015, a BET Bromodomain Inhibitor for the Treatment of Hematologic Malignancies

Lausanne, Switzerland – OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient. OTX015 is a synthetic orally administered small molecule which targets BET bromodomain proteins 2/3/4, which are considered potential cancer targets because of their pivotal role in regulating the transcription of growth-promoting and cell cycle regulators, especially c-MYC. Phase I trials of OTX015 in healthy volunteers have already been completed.

Read more »

Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precurser Cells in Patients with Active Rheumatoid Arthritis

Melbourne, Australia - Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration (FDA) to commence a Phase 2 clinical trial evaluating a single intravenous infusion of allogeneic, or “off-the-shelf”, Mesenchymal Precursor Cells (MPCs) for the treatment of active rheumatoid arthritis.

Read more »

Prosensa Achieves Orphan Drug Status on its Entire Duchenne Muscular Dystrophy Portfolio

Leiden, The Netherlands  – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan drug designation in the EU and the US for all of its compounds for the treatment of Duchenne muscular dystrophy (DMD).

Read more »

4-Antibody AG and the Ludwig Institute

Basel, Switzerland and New York, USA – 4-Antibody AG and the Ludwig Institute for Cancer Research (the Ludwig Institute) today announced the signing of a multi-target R&D collaboration with Recepta Biopharma SA, the leading Brazilian developer of therapeutic antibodies founded by the Ludwig Institute and Brazilian investors. This represents an expansion of a partnership the Ludwig Institute and 4-Antibody initiated over a year ago. Financial details were not disclosed.

Read more »

AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial forHerpes Drug Pritelivir

Wuppertal, Germany – AiCuris announced today that it has achieved over 50% patient enrollment in the second clinical efficacy trial with its novel anti-herpes simplex virus (HSV) drug pritelivir (formerly known as AIC316). Trial AIC316-01-II-02 (NCT01658826, www.clinicaltrials.gov) compares the potency of pritelivir in reducing genital HSV shedding with valacyclovir.

Read more »

Positive results from the BI-505 phase I study in multiple myeloma

Lund, Sweden – BioInvent International (OMXS:BINV) announced today the first results from the BI-505 phase I study in patients with multiple myeloma. The study has reached a final stage and the preliminary analysis shows that BI-505 has an advantageous safety profile. In cohorts where extended therapy was available, 24 % of the patients had stable disease for at least two months, indicating effect of BI-505. The final conclusions of the study will be available at a later time-point. 

Read more »

Dezima Pharma in-licenses CETP Inhibitor Program

Naarden, The Netherlands – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.

Read more »

Australian Cardiac Monitoring Company Reports Large Reduction in Sepsis Deaths Using Its Non-invasive Heart Monitor

Sydney, Australia − Non-invasive cardiac monitoring company Uscom Limited (ASX:UCM) today announced the international presentation of independent data that confirms significant life-saving and cost reduction associated with USCOM guided treatment of sepsis and septic shock.

Read more »

Synthon Biopharmaceuticals reports positive early results with its second generation HER2-antibody-drug conjugate

Nijmegen, the Netherlands − Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs). In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon has reported complete tumor remission. Toxicity experiments conducted to-date have revealed Best-in-Class potential with a greatly improved therapeutic index compared to other armed antibodies, due to an impressive safety profile. The company has also opened a state-of-the-art GMP facility in Nijmegen for the production of ADCs up to phase III clinical trials and early launches. 

Read more »

College Hill Welcomes Three New Employees to its London Life Sciences Team

London: College Hill, part of the international business communications consultancy, College Group, is pleased to announce the recent appointment of Stefanie Bacher, Katherine Granger and Donia Al Saffar to its Life Sciences team. Stefanie and Katherine join as Account Directors while Donia joins the team as a Junior Account Executive. All three are based in London.

Read more »

College Hill Life Sciences Expands its International IR/FPR Offering with Appointment of Veronica Sellar

London: The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, has strengthened and expanded its Investors Relations and Financial PR offering with the appointment of Veronica Sellar as Partner.

Read more »

College Hill Life Sciences Appoints New Partner

The Life Sciences team of College Hill, part of the international business communications consultancy, College Group, has strengthened and expanded its Investors Relations and Financial PR offering with the appointment of Veronica Sellar as Partner.

Read more »

Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its anti-VEGF DARPin MP0112 in Diabetic Macular Edema

Zurich-Schlieren, Switzerland – Molecular Partners announced today that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME) have been published on-line in The American Journal of Ophthalmology (AJO).

Read more »

P.L.E.A.S.E.® Laser Device Suitable for Painless Antigen Application

Ruggell, Liechtenstein – Pantec Biosolutions AG, the manufacturer of P.L.E.A.S.E.® Professional, a portable laser device for the precise microporation of the skin, has contributed to three scientific publications illustrating the effectiveness of the technology for a new form of immunotherapy in an allergic asthma mouse model.

Read more »

The Madness that is “JP Morgan week in San Francisco”

Partner Melanie Toyne Sewell went to one of the largest investor and partnering conferences in the healthcare calendar in San Francisco in from 7 – 10 January 2013.

Read more »

2012 – An award-winning year for College Hill Life Sciences clients

2012 was a great year for many of College Hill Life Sciences’ clients, a fact demonstrated by the number of companies picking up prestigious awards.

Read more »

Mesoblast’s Neofuse Stem Cell Product Shows Positive Results in Phase 2 Lumbar Spinal Fusion Trial

Melbourne, Australia – Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that its Phase 2 clinical trial for lumbar spinal fusion had successfully met its safety and efficacy endpoints. 

Read more »

BioGasol ApS Completes First Carbofrac™ Reactor Sale to Sweetwater Energy

Copenhagen, Denmark – BioGasol ApS, the renewable energy company, today announced the completion of the first sale of its Carbofrac™ 400 pretreatment reactor to Sweetwater Energy, Inc. The Rochester, NY-based cellulosic sugar producer will use the reactor, designed to treat lignocellulosic feedstock before fermentation, as part of a decentralised sugar manufacturing unit for use by Ace Ethanol, a Stanley, WI-based corn ethanol producer.

Read more »

Thomas Monath and Farshad Guirakhoo Join Hookipa Biotech as Chief Medical Officer and Chief Scientific Officer

Vienna, Austria – Hookipa Biotech AG, a vaccine biotech start up pioneering a new class of vaccines, today announced the appointment of two new members to its Management team: Thomas P. Monath as Chief Medical Officer and Farshad Guirakhoo as Chief Scientific Officer.

Read more »

Hookipa Announces Formation of Scientific Advisory Board

Vienna, Austria – Hookipa Biotech AG, a vaccine biotech start up pioneering a new class of vaccines, today announced the formation of its Scientific Advisory Board (SAB).  The SAB is chaired by Emeritus Prof. Dr. Paul-Henri Lambert (PhD), former Chief of Vaccine Research and Development for the WHO Global Program for Vaccines and Immunizations.  The members include distinguished scientists and experienced industrial experts:  Emeritus Prof. Dr. Stanley Plotkin (MD), Prof. Dr. Michael Mach (PhD), Dr. Arnaud Marchant (MD, PhD) and Prof. Dr. Franz Heinz (PhD).  The SAB will provide expert advice to the Company on a broad range of topics related to research, development, manufacturing, quality control, medical, regulatory, and commercial aspects of the Company’s Vaxwave® platform and specific vaccine targets.

Read more »

Clinical Network Services (CNS) acquires New Zealand partner BELTAS’ business assets

Brisbane, Australia - Clinical Network Services (CNS), an Australian based CRO offering integrated development services in the planning, implementation and delivery of Phase 1 and 2 trials, today announced that it has acquired the business assets of its erstwhile New Zealand partner BELTAS, a CRO based in Auckland. Terms of the deal were not disclosed.

Read more »

Telormedix Granted IND for Phase II in Bladder Cancer

Bioggio, Switzerland − Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has received FDA authorisation (IND: permission to use an investigational new drug in humans) for a Phase II trial of its lead product TMX-101, a TLR-7 agonist, in CIS (carcinoma in situ) in the bladder.

Read more »

Prosensa to Present at J.P. Morgan Healthcare Conference

Leiden, The Netherlands – Prosensa, the private Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that Hans Schikan, Chief Executive Officer, will be presenting at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.

Read more »